{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:57:41Z","timestamp":1794412661322,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02634-3","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:36:40Z","timestamp":1775713000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Irinotecan with trifluridine\/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study"],"prefix":"10.1038","volume":"11","author":[{"given":"Wenwei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoye","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3302-6023","authenticated-orcid":false,"given":"Yongkun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2634_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2634_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in China, 2022. J. Natl. Cancer Cent. 4, 47\u201353 (2024).","journal-title":"J. Natl. Cancer Cent."},{"key":"2634_CR3","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335\u20132342 (2004).","journal-title":"N. Engl. J. Med"},{"key":"2634_CR4","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013\u20132019 (2008).","journal-title":"J. Clin. Oncol."},{"key":"2634_CR5","doi-asserted-by":"crossref","unstructured":"Ohishi, T. et al. Current targeted therapy for metastatic colorectal cancer. Int. J. Mol. Sci. 24, 1702 (2023).","DOI":"10.3390\/ijms24021702"},{"key":"2634_CR6","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook, A. P. et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with kras wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317, 2392\u20132401 (2017).","journal-title":"JAMA"},{"key":"2634_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106330","volume":"182","author":"M Gao","year":"2022","unstructured":"Gao, M. et al. Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: a meta-analysis. Pharm. Res. 182, 106330 (2022).","journal-title":"Pharm. Res."},{"key":"2634_CR8","doi-asserted-by":"publisher","first-page":"1032314","DOI":"10.3389\/fimmu.2022.1032314","volume":"13","author":"W Hou","year":"2022","unstructured":"Hou, W., Yi, C. & Zhu, H. Predictive biomarkers of colon cancer immunotherapy: Present and future. Front. Immunol. 13, 1032314 (2022).","journal-title":"Front. Immunol."},{"key":"2634_CR9","first-page":"363","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. 69, 363\u2013385 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"2634_CR10","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.tranon.2021.101174","volume":"14","author":"Y Xi","year":"2021","unstructured":"Xi, Y. & Xu, P. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol. 14, 101174 (2021).","journal-title":"Transl. Oncol."},{"key":"2634_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107823","volume":"224","author":"S Chakrabarti","year":"2021","unstructured":"Chakrabarti, S. et al. TAS-102: a resurrected novel fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies. Pharm. Ther. 224, 107823 (2021).","journal-title":"Pharm. Ther."},{"key":"2634_CR12","first-page":"545","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura, T. et al. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J. Mol. Med. 13, 545\u2013549 (2004).","journal-title":"Int J. Mol. Med."},{"key":"2634_CR13","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2634_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu, J. et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J. Clin. Oncol. 36, 350\u2013358 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2634_CR15","first-page":"1437","volume":"35","author":"M Nukatsuka","year":"2015","unstructured":"Nukatsuka, M. et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res. 35, 1437\u20131445 (2015).","journal-title":"Anticancer Res."},{"key":"2634_CR16","first-page":"2135","volume":"33","author":"H Tsukihara","year":"2015","unstructured":"Tsukihara, H. et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol. Rep. 33, 2135\u20132142 (2015).","journal-title":"Oncol. Rep."},{"key":"2634_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejca.2006.08.022","volume":"43","author":"OH Temmink","year":"2007","unstructured":"Temmink, O. H., Hoebe, E. K., Fukushima, M. & Peters, G. J. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur. J. Cancer 43, 175\u2013183 (2007).","journal-title":"Eur. J. Cancer"},{"key":"2634_CR18","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager, G. W. et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388, 1657\u20131667 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2634_CR19","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41416-024-02885-3","volume":"131","author":"B Li","year":"2024","unstructured":"Li, B. et al. Phase II study of irinotecan, trifluridine\/tipiracil (TAS-102) plus bevacizumab as a later-line therapy for patients with metastatic colorectal cancer (mCRC): a prospective single-center explorative study. Br. J. Cancer 131, 1775\u20131780 (2024).","journal-title":"Br. J. Cancer"},{"key":"2634_CR20","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41416-024-02845-x","volume":"131","author":"PM Boland","year":"2024","unstructured":"Boland, P. M. et al. TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial. Br. J. Cancer 131, 1290\u20131297 (2024).","journal-title":"Br. J. Cancer"},{"key":"2634_CR21","doi-asserted-by":"publisher","first-page":"e1108","DOI":"10.1093\/oncolo\/oyad143","volume":"28","author":"H Taniguchi","year":"2023","unstructured":"Taniguchi, H. et al. Bevacizumab, Irinotecan, and Biweekly Trifluridine\/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study. Oncologist 28, e1108\u2013e1113 (2023).","journal-title":"Oncologist"},{"key":"2634_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s10637-024-01443-1","volume":"42","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Phase I study of trifluridine\/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer. Investig. N. Drugs 42, 454\u2013461 (2024).","journal-title":"Investig. N. Drugs"},{"key":"2634_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna, J. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14, 29\u201337 (2013).","journal-title":"Lancet Oncol."},{"key":"2634_CR24","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem, E. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30, 3499\u20133506 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2634_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero, J. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 16, 499\u2013508 (2015).","journal-title":"Lancet Oncol."},{"key":"2634_CR26","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","volume":"19","author":"RH Xu","year":"2018","unstructured":"Xu, R. H. et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol. 19, 660\u2013671 (2018).","journal-title":"Lancet Oncol."},{"key":"2634_CR27","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41416-023-02212-2","volume":"128","author":"Y Kuboki","year":"2023","unstructured":"Kuboki, Y. et al. Trifluridine\/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. Br. J. Cancer 128, 1897\u20131905 (2023).","journal-title":"Br. J. Cancer"},{"key":"2634_CR28","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1007\/s10637-015-0271-1","volume":"33","author":"T Doi","year":"2015","unstructured":"Doi, T. et al. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Investig. N. Drugs 33, 1068\u20131077 (2015).","journal-title":"Investig. N. Drugs"},{"key":"2634_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000171605","volume":"15","author":"P Distler","year":"1997","unstructured":"Distler, P. & Holt, P. R. Are right- and left-sided colon neoplasms distinct tumors? Dig. Dis. 15, 302\u2013311 (1997).","journal-title":"Dig. Dis."},{"key":"2634_CR30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1200\/JCO.2010.30.1366","volume":"29","author":"G Hutchins","year":"2011","unstructured":"Hutchins, G. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29, 1261\u20131270 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2634_CR31","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"A Falcone","year":"2007","unstructured":"Falcone, A. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25, 1670\u20131676 (2007).","journal-title":"J. Clin. Oncol."},{"key":"2634_CR32","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis, F. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med. 371, 1609\u20131618 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2634_CR33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini, C. et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 21, 497\u2013507 (2020).","journal-title":"Lancet Oncol."},{"key":"2634_CR34","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-19-2743","volume":"26","author":"AM Varghese","year":"2020","unstructured":"Varghese, A. M. et al. Phase I study of trifluridine\/tipiracil plus irinotecan and bevacizumab in advanced gastrointestinal tumors. Clin. Cancer Res. 26, 1555\u20131562 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2634_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro, K. et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol. 11, 853\u2013860 (2010).","journal-title":"Lancet Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02634-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02634-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02634-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:36:44Z","timestamp":1775713004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02634-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2634"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02634-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}